Re: Armstrong AJ, Petrylak DP, Shore ND, Et Al. ARCHES 5-Year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol 2026. in Press. Http://Dx.doi.org/10.1016/j.eururo.2025.12.021.